Indian Pharma Q1FY27: Revenue up, but profits to dip, says report
Indian pharma firms are set for improved Q1FY27 revenues, but a Goldman Sachs report warns of declining margins. This is due to an unfavorable product mix, loss of high-margin items, and rising input…
Read the full articleYou might also wanna read
Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman Sachs
New Delhi [India], July 9 (ANI): Indian pharmaceutical companies are expected to report improved revenues in the first quarter of FY2026-27,
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
This big pharma stock looks attractive for income investors -- but it comes with some risk.
EMS sector likely to report 21% revenue growth; margins may stay under pressure: Kotak
New Delhi [India], July 10 (ANI): India's electronic manufacturing services (EMS) sector is likely to post 21 per cent year-on-year revenue
India’s growth momentum may slow in H2 FY27 as demand risks rise: Nuvama
Nuvama expects India’s growth to moderate in H2 FY27 as the impact of GST cuts fades and demand faces headwinds from El Nino and weaker inco
Agrochemical exporters to outperform domestic peers amid muted Q1FY27 earnings: Report
New Delhi [India], July 10 (ANI): India's agrochemical sector is likely to report muted earnings in the first quarter of FY27, with exporter
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow proc
Comments
Sign in to join the conversation.
No comments yet. Be the first.